Back to Search Start Over

Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson’s Disease Patients: A 2-Year Follow-Up Study

Authors :
Diego Santos-García
Teresa de Deus Fonticoba
Carlos Cores Bartolomé
Maria J. Feal Painceiras
Ester Suárez Castro
Héctor Canfield
Cristina Martínez Miró
Silvia Jesús
Miquel Aguilar
Pau Pastor
Lluís Planellas
Marina Cosgaya
Juan García Caldentey
Nuria Caballol
Ines Legarda
Jorge Hernández-Vara
Iria Cabo
Lydia López Manzanares
Isabel González Aramburu
Maria A. Ávila Rivera
Víctor Gómez Mayordomo
Víctor Nogueira
Víctor Puente
Julio Dotor García-Soto
Carmen Borrué
Berta Solano Vila
María Álvarez Sauco
Lydia Vela
Sonia Escalante
Esther Cubo
Francisco Carrillo Padilla
Juan C. Martínez Castrillo
Pilar Sánchez Alonso
Maria G. Alonso Losada
Nuria López Ariztegui
Itziar Gastón
Jaime Kulisevsky
Marta Blázquez Estrada
Manuel Seijo
Javier Rúiz Martínez
Caridad Valero
Mónica Kurtis
Oriol de Fábregues
Jessica González Ardura
Ruben Alonso Redondo
Carlos Ordás
Luis M. López Díaz
Darrian McAfee
Pablo Martinez-Martin
Pablo Mir
COPPADIS Study Group
Source :
Diagnostics, Vol 12, Iss 5, p 1147 (2022)
Publication Year :
2022
Publisher :
MDPI AG, 2022.

Abstract

Objective: The aim of the present study was to analyze the progression of non-motor symptoms (NMS) burden in Parkinson’s disease (PD) patients regarding the development of motor fluctuations (MF). Methods: PD patients without MF at baseline, who were recruited from January 2016 to November 2017 (V0) and evaluated again at a 2-year follow-up (V2) from 35 centers of Spain from the COPPADIS cohort, were included in this analysis. MF development at V2 was defined as a score ≥ 1 in the item-39 of the UPDRS-Part IV, whereas NMS burden was defined according to the Non-motor Symptoms Scale (NMSS) total score. Results: Three hundred and thirty PD patients (62.67 ± 8.7 years old; 58.8% males) were included. From V0 to V2, 27.6% of the patients developed MF. The mean NMSS total score at baseline was higher in those patients who developed MF after the 2-year follow-up (46.34 ± 36.48 vs. 34.3 ± 29.07; p = 0.001). A greater increase in the NMSS total score from V0 to V2 was observed in patients who developed MF (+16.07 ± 37.37) compared to those who did not develop MF (+6.2 ± 25.8) (p = 0.021). Development of MF after a 2-year follow-up was associated with an increase in the NMSS total score (β = 0.128; p = 0.046) after adjustment to age, gender, years from symptoms onset, levodopa equivalent daily dose (LEDD) and the NMSS total score at baseline, and the change in LEDD from V0 to V2. Conclusions: In PD patients, the development of MF is associated with a greater increase in the NMS burden after a 2-year follow-up.

Details

Language :
English
ISSN :
20754418
Volume :
12
Issue :
5
Database :
Directory of Open Access Journals
Journal :
Diagnostics
Publication Type :
Academic Journal
Accession number :
edsdoj.1218cb6a14ba4fd18f2a0c554798e52f
Document Type :
article
Full Text :
https://doi.org/10.3390/diagnostics12051147